[go: up one dir, main page]

DK1221952T3 - Anvendelse af en antagonist til centrale cannaboidreceptorer med henblik på fremstilling af lægemidler - Google Patents

Anvendelse af en antagonist til centrale cannaboidreceptorer med henblik på fremstilling af lægemidler

Info

Publication number
DK1221952T3
DK1221952T3 DK00966200T DK00966200T DK1221952T3 DK 1221952 T3 DK1221952 T3 DK 1221952T3 DK 00966200 T DK00966200 T DK 00966200T DK 00966200 T DK00966200 T DK 00966200T DK 1221952 T3 DK1221952 T3 DK 1221952T3
Authority
DK
Denmark
Prior art keywords
cannaboid
antagonist
receptors
drugs
manufacture
Prior art date
Application number
DK00966200T
Other languages
English (en)
Inventor
Bernard Bourrie
Pierre Casellas
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Application granted granted Critical
Publication of DK1221952T3 publication Critical patent/DK1221952T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
DK00966200T 1999-10-01 2000-09-27 Anvendelse af en antagonist til centrale cannaboidreceptorer med henblik på fremstilling af lægemidler DK1221952T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9912415A FR2799124B1 (fr) 1999-10-01 1999-10-01 Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
PCT/FR2000/002662 WO2001024798A1 (fr) 1999-10-01 2000-09-27 Utilisation d'un antagoniste des recepteurs aux cannabinoïdes centraux pour la preparation de medicaments

Publications (1)

Publication Number Publication Date
DK1221952T3 true DK1221952T3 (da) 2005-08-29

Family

ID=9550596

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00966200T DK1221952T3 (da) 1999-10-01 2000-09-27 Anvendelse af en antagonist til centrale cannaboidreceptorer med henblik på fremstilling af lægemidler

Country Status (12)

Country Link
US (1) US6642258B1 (da)
EP (1) EP1221952B1 (da)
JP (1) JP2003510361A (da)
AR (1) AR025883A1 (da)
AT (1) ATE295170T1 (da)
AU (1) AU7667300A (da)
DE (1) DE60020145T2 (da)
DK (1) DK1221952T3 (da)
ES (1) ES2240176T3 (da)
FR (1) FR2799124B1 (da)
PT (1) PT1221952E (da)
WO (1) WO2001024798A1 (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003075917A1 (en) 2002-03-08 2003-09-18 Signal Pharmaceuticals, Inc. Combination therapy for treating, preventing or managing proliferative disorders and cancers
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
US7247628B2 (en) 2002-12-12 2007-07-24 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
US7329658B2 (en) 2003-02-06 2008-02-12 Pfizer Inc Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) 2003-02-10 2007-02-13 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US7268133B2 (en) 2003-04-23 2007-09-11 Pfizer, Inc. Patent Department Cannabinoid receptor ligands and uses thereof
ATE496901T1 (de) * 2003-05-20 2011-02-15 Univ Tennessee Res Foundation Cannabinoidderivate, verfahren zu deren herstellung und deren verwendung
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
FR2861303A1 (fr) * 2003-10-24 2005-04-29 Sanofi Synthelabo Utilisation d'un derive de pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement du syndrome metabolique
WO2006060192A2 (en) * 2004-11-30 2006-06-08 Bayer Pharmaceuticals Corporation Pyrazole derivatives
CN101115726A (zh) 2004-12-03 2008-01-30 先灵公司 作为cb1拮抗剂的取代哌嗪
US9066847B2 (en) * 2007-01-05 2015-06-30 Aceirx Pharmaceuticals, Inc. Storage and dispensing devices for administration of oral transmucosal dosage forms
US9289583B2 (en) 2006-01-06 2016-03-22 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8357114B2 (en) 2006-01-06 2013-01-22 Acelrx Pharmaceuticals, Inc. Drug dispensing device with flexible push rod
US8252328B2 (en) 2006-01-06 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8202535B2 (en) 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US8753308B2 (en) 2006-01-06 2014-06-17 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US7897601B2 (en) 2006-01-18 2011-03-01 Intervet, Inc. Cannabinoid receptor modulators
WO2008130616A2 (en) * 2007-04-19 2008-10-30 Schering Corporation Diaryl morpholines as cb1 modulators
EP2548874A3 (en) * 2007-06-28 2013-05-15 Intervet International B.V. Substituted piperazines as CB1 antagonists
WO2009005671A2 (en) * 2007-06-28 2009-01-08 Schering Corporation Substituted piperazines as cb1 antagonists
EP2182902B1 (en) * 2007-08-07 2015-01-07 Acelrx Pharmaceuticals, Inc. Compositions comprising sufentanil and triazolam for procedural sedation and analgesia using oral transmucosal dosage forms
US8945592B2 (en) * 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
US20110091544A1 (en) * 2009-10-16 2011-04-21 Acelrx Pharmaceuticals, Inc. Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting
WO2013068371A1 (en) 2011-11-08 2013-05-16 Intervet International B.V. Soft chewable dosage form compositions of cannabinoid receptor type 1 (cb-1) antagonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2692575B1 (fr) * 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
FR2713225B1 (fr) * 1993-12-02 1996-03-01 Sanofi Sa N-pipéridino-3-pyrazolecarboxamide substitué.
US5596106A (en) * 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
DE19706903A1 (de) * 1997-02-21 1998-08-27 Bayer Ag Verwendung von bekannten Agonisten des zentralen Cannabinoid-Rezeptors CB 1
FR2783246B1 (fr) * 1998-09-11 2000-11-17 Aventis Pharma Sa Derives d'azetidine, leur preparation et les medicaments les contenant
FR2789079B3 (fr) * 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant

Also Published As

Publication number Publication date
DE60020145T2 (de) 2006-02-16
ATE295170T1 (de) 2005-05-15
AU7667300A (en) 2001-05-10
DE60020145D1 (de) 2005-06-16
FR2799124B1 (fr) 2004-08-13
FR2799124A1 (fr) 2001-04-06
WO2001024798A1 (fr) 2001-04-12
JP2003510361A (ja) 2003-03-18
ES2240176T3 (es) 2005-10-16
PT1221952E (pt) 2005-08-31
EP1221952B1 (fr) 2005-05-11
EP1221952A1 (fr) 2002-07-17
AR025883A1 (es) 2002-12-18
US6642258B1 (en) 2003-11-04

Similar Documents

Publication Publication Date Title
DK1221952T3 (da) Anvendelse af en antagonist til centrale cannaboidreceptorer med henblik på fremstilling af lægemidler
DK1208095T3 (da) Dibenzopyraner som glucocorticoidreceptorantagonister til behandling af diabetes
PT1131291E (pt) Antagonistas iii do receptor 4-aroil-piperidin-ccr-3
PT1009732E (pt) 1-amino-alquilciclo-hexanos antagonistas do receptor nmda
DK1257275T3 (da) Anvendelse af en antagonist til centrale cannabiboidreceptorer til fremstilling af lægemidler, der er nyttige for at göre det lettere at ophöre med brug af tobak
CY2010003I1 (el) Αγωνιστες των βητα-2 αδρενεργικων υποδοχεων
DE60026169D1 (de) Selektive neurokinin-antagonisten
ATE368659T1 (de) Thrombinrezeptorantagonisten
PT1224174E (pt) Derivados de benzodiazepina como antagonistas do receptor metabotropico do glutamato
PT1347760E (pt) Composicoes farmaceuticas de agonista do receptor de nmda
DK1200073T3 (da) Selektive iGluR5-receptorantagonister til behandling af migræne
NO20004503D0 (no) Vitronectin-reseptor-antagonister
NO20013997D0 (no) Reseptoranalyse
NO20015779L (no) Bradykinin-reseptorantagonister
IT1316831B1 (it) Dispositivo per il collegamento di due parti costruttive
NO20016077L (no) Makrofag-oppfanger-reseptorantagonister
DK1475379T3 (da) Anvendelse af scopinesterderivater til fremstilling af lægemidler
PT1171419E (pt) Derivados de bifenilo como antagonistas do receptor da neuroquinina-1
NO20020644D0 (no) Nye integrinreseptor-antagonister
ATE277043T1 (de) Vitronectin rezeptor antagonist
NO20021113D0 (no) Vitronectin-reseptor-antagonister
NO20021295D0 (no) Nikotinsyreacetylcholin-reseptor
NO20010620D0 (no) Vitronektinreseptor-antagonister
DK1385512T3 (da) Anvendelse af pyridoindolonderivater til fremstilling af anticancerlægemidler
DE60209885D1 (de) Crf receptor antagonisten